Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishituka, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura, Takenori Nakaya, Toshiro Sakata, Kazuyuki Shimada, Kunio Shirato, for the Japan EPA lipid intervention study (JELIS) Investigators

Summary

Background  Epidemiological and clinical evidence suggests that an increased intake of long-chain n-3 fatty acids protects against mortality from coronary artery disease. We aimed to test the hypothesis that long-term use of eicosapentaenoic acid (EPA) is effective for prevention of major coronary events in hypercholesterolaemic patients in Japan who consume a large amount of fish.

Methods  18 645 patients with a total cholesterol of 6·5 mmol/L or greater were recruited from local physicians throughout Japan between 1996 and 1999. Patients were randomly assigned to receive either 1800 mg of EPA daily with statin (EPA group; n=9326) or statin only (controls; n=9319) with a 5-year follow-up. The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting. Analysis was by intention-to-treat. The study was registered at clinicaltrials.gov, number NCT00231738.

Findings  At mean follow-up of 4·6 years, we detected the primary endpoint in 262 (2·8%) patients in the EPA group and 324 (3·5%) in controls—a 19% relative reduction in major coronary events (p=0·011). Post-treatment LDL cholesterol concentrations decreased 25%, from 4·7 mmol/L in both groups. Serum LDL cholesterol was not a significant factor in a reduction of risk for major coronary events. Unstable angina and non-fatal coronary events were also significantly reduced in the EPA group. Sudden cardiac death and coronary death did not differ between groups. In patients with a history of coronary artery disease who were given EPA treatment, major coronary events were reduced by 19% (secondary prevention subgroup: 158 [8·7%] in the EPA group vs 197 [10·7%] in the control group; p=0·048). In patients with no history of coronary artery disease, EPA treatment reduced major coronary events by 18%, but this finding was not significant (104 [1·4%] in the EPA group vs 127 [1·7%] in the control group; p=0·132).

Interpretation  EPA is a promising treatment for prevention of major coronary events, and especially non-fatal coronary events, in Japanese hypercholesterolaemic patients.

Introduction

Epidemiological and clinical evidence suggests a significant inverse association between long-term intake of long-chain n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and mortality associated with coronary artery disease. 1–7 Thus, the consumption of fish or fish-oil could protect against major events associated with coronary artery disease, especially fatal myocardial infarction and sudden cardiac death. Two large-scale secondary prevention trials, the Diet and Reinfarction Trial and the Gruppo Italiano per lo Studio della Sopravivenza nell’Infarto Miocardico-Prevenzione Trial, reported that increased consumption of fish or fish-oil supplements reduced coronary death in postinfarction patients. 8,9 No randomised trials have examined the effects of n-3 polyunsaturated fatty acids on major coronary events in a high-risk, primary prevention population.

EPA ethyl ester, which is purified from n-3 polyunsaturated fatty acids present in fish oil, is approved by Japan’s Ministry of Health, Labour, and Welfare as a treatment for hyperlipidaemia and peripheral artery disease. The biological functions of EPA include reduction of platelet aggregation, 10,11 vasodilation, 12,13 antiproliferation, 14 plaque-stabilisation, 15 and reduction in lipid action. 16,17 Therefore the preventive effects of EPA on major cardiovascular events are of both clinical interest and therapeutic importance.

Primary and secondary prevention trials have proved that cholesterol-lowering treatment with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase—statins—reduces the risk of all-cause mortality and major cardiovascular events in patients with a wide range of cholesterol concentrations, whether or not they have had coronary artery disease. 18–21 Thus, statins are now established as the first-line treatment for hyperlipidaemia. 22 Preliminary data for treatment with a combination of n-3 polyunsaturated fatty acids and statins have shown beneficial effects on the lipid profiles of patients with a mixed type of hyperlipidaemia, 23–25 however, no major long-term inter-
ventional trial has yet investigated whether the addition of EPA to conventional statin treatment would yield an incremental clinical benefit. The Japan EPA Lipid Intervention Study (JELIS) tests the hypothesis that long-term use of EPA is effective in reduction of major coronary events in Japanese hypercholesterolaemic patients given statins.

Methods
Study design and patients
We did a prospective, randomised open-label, blinded endpoint evaluation (PROBE).26 Our study design, and inclusion and exclusion criteria are described in detail elsewhere.27 We recruited 19 466 hypercholesterolaemic patients through local physicians from all regions of Japan between November, 1996, and November, 1999. Figure 1 shows the trial profile. The participants consisted of 5859 men (aged 40–75 years) and 12 786 postmenopausal women (aged up to 75 years), with or without coronary artery disease, which was defined as previous myocardial infarction, coronary interventions, or confirmed angina pectoris. Informed written consent was obtained from all eligible patients before random assignment to either the EPA treatment or control groups.

Eligibility criteria were total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater. Exclusion criteria were: acute myocardial infarction within the past 6 months, unstable angina pectoris, a history or complication of serious heart disease (such as severe arrhythmia, heart failure, cardiomyopathy, valvular disease, or congenital disease), cardiovascular reconstruction within the past 6 months, cerebrovascular disorders within the past 6 months, complications of serious hepatic or renal disease, malignant disease, uncontrollable diabetes, hyperlipidaemia due to other disorders, hyperlipidaemia caused by drugs such as steroid hormones, haemorrhage (including haemophilia, capillary fragility, gastrointestinal ulcer, urinary tract haemorrhage, haemoptysis, and vitreous haemorrhage), haemorrhagic diathesis, hypersensitivity to the study drug formulation, patients’ intention to undergo surgery, and judgment by the physician in charge that a patient was inappropriate for the study.

The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting. Secondary endpoints (all-cause mortality, mortality and morbidity of coronary artery disease, stroke, peripheral artery disease, and cancer) are not reported here.

Procedures
We used the statistical coordination centre at the Toyama Medical and Pharmaceutical University to manage patient registration (including confirmation of eligibility criteria), operation of the randomisation scheme, and data management. We used permuted-block randomisation with a block size of four. Blocks were assigned according to the number of participants enrolled at each centre. Patients were divided into two subgroups: one with coronary artery disease (secondary prevention; n=3664) and one without (primary prevention; n=14 981), and stratified accordingly. Patients were randomly assigned to receive EPA with statin (EPA group) or statin alone (controls). All patients first underwent 4–8 weeks of washout from antihyperlipidaemic drugs. Patients also received appropriate dietary advice.

All patients received 10 mg of pravastatin or 5 mg of simvastatin once daily as first-line treatment. These statins were available in Japan at the initiation of this study, and these doses were recommended by the Ministry of Health, Labour, and Welfare. For serious hypercholesterolaemia (defined as uncontrolled), this daily dose was increased to 20 mg pravastatin or 10 mg simvastatin. No treatment with other antihyperlipidaemic drugs was allowed during the study. EPA was given at a dose of 600 mg, three times a day after meals (to a total of 1800 mg per day). We used capsules that contained 300 mg of highly purified (>98%) EPA ethyl ester (Mochida Pharmaceuticals, Tokyo, Japan).

Local physicians monitored compliance with dietary advice and medication, and noted adverse events at every clinic visit. Clinical endpoints and severe adverse events reported by local physicians were checked by members of a regional organising committee in a blinded fashion. Then, an endpoints adjudication committee (see webappendix), consisting of three expert cardiologists and one expert neurologist, confirmed them once a year without knowledge of the See Online for webappendix
treatment allocation. The study was approved by an external data and safety monitoring board, by institutional review boards at all hospitals, and by regional organising committees. The data and safety monitoring board also monitored the rate of endpoints. The study was approved by an institutional review board at all hospitals, and by an external data and safety monitoring board, by the regional organising committees. The data and safety monitoring board also monitored the rate of endpoints.

We sampled blood to measure serum lipid at 6 and 12 months, and then every year until the final follow-up visits. Plasma total fatty acid concentrations for all patients who gave informed consent were measured with capillary gas chromatography every year at a central laboratory.

### Table 1: Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Controls (n=9319)</th>
<th>EPA treatment (n=9326)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63 (9)</td>
<td>61 (8)</td>
</tr>
<tr>
<td>Male</td>
<td>2908 (31%)</td>
<td>2953 (32%)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24 (3)</td>
<td>24 (3)</td>
</tr>
<tr>
<td><strong>Cardiovascular history</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>502 (5%)</td>
<td>548 (6%)</td>
</tr>
<tr>
<td>Angina</td>
<td>1484 (16%)</td>
<td>1419 (15%)</td>
</tr>
<tr>
<td>CABG or PTCA</td>
<td>433 (5%)</td>
<td>462 (5%)</td>
</tr>
<tr>
<td><strong>Risk factors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>1700 (18%)</td>
<td>1830 (20%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1524 (16%)</td>
<td>1516 (16%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3282 (35%)</td>
<td>3329 (36%)</td>
</tr>
<tr>
<td><strong>Serum lipid values</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>7.11 (0.68)</td>
<td>7.11 (0.67)</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/L)</td>
<td>4.70 (0.75)</td>
<td>4.69 (0.76)</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/L)</td>
<td>1.51 (0.44)</td>
<td>1.52 (0.46)</td>
</tr>
<tr>
<td>Triglyceride (mmol/L)*</td>
<td>1.74 (1.25-2.49)</td>
<td>1.73 (1.23-2.48)</td>
</tr>
<tr>
<td><strong>Blood pressure</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic (mm Hg)</td>
<td>135 (21)</td>
<td>135 (21)</td>
</tr>
<tr>
<td>Diastolic (mm Hg)</td>
<td>79 (13)</td>
<td>79 (13)</td>
</tr>
<tr>
<td><strong>HMG CoA RI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pravastatin</td>
<td>5553 (60%)</td>
<td>5523 (60%)</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>3417 (32%)</td>
<td>3272 (36%)</td>
</tr>
<tr>
<td>Other statin</td>
<td>128 (1%)</td>
<td>110 (1%)</td>
</tr>
<tr>
<td><strong>Medication use</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiplatelet agent</td>
<td>1342 (14%)</td>
<td>1258 (13%)</td>
</tr>
<tr>
<td>Calcium antagonist</td>
<td>2837 (30%)</td>
<td>2796 (30%)</td>
</tr>
<tr>
<td>β blocker</td>
<td>791 (8%)</td>
<td>794 (9%)</td>
</tr>
<tr>
<td>Other antihypertensive agents</td>
<td>2424 (26%)</td>
<td>2366 (25%)</td>
</tr>
<tr>
<td>Nitrate</td>
<td>925 (10%)</td>
<td>863 (9%)</td>
</tr>
<tr>
<td>Hypoglycaemic agents</td>
<td>1126 (12%)</td>
<td>1081 (12%)</td>
</tr>
</tbody>
</table>

Data are number of patients (%) or mean (SD), unless otherwise indicated. CABG=coronary-artery bypass grafting. PTCA=percutaneous transluminal coronary angioplasty. LDL=low-density lipoprotein. HDL=high-density lipoprotein. IQR=interquartile range. HMG CoA RI=3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. BMI=body-mass index, which is weight in kg divided by the square of height in metres. *Median (IQR).

### Statistical analysis

We used a two-sided test at the 5% significance level to estimate that the number of enrolled patients would give the study a statistical power of 80% for detection of a relative reduction of 25% in the primary endpoint rate, when the EPA group was compared with controls. The event rate of the primary endpoint in the control group was assumed to be 0.58% per year for primary prevention and 2.13% per year for secondary prevention; the proportion of primary and secondary prevention strata was assumed to be 4:1. The accrual period was assumed to be 3 years with a follow-up of 5 years for all patients. All analyses were based on the intention-to-treat principle. Time-to-event data were analysed with the Kaplan–Meier method and the log-rank test. The hazard ratio and its 95% confidence interval were computed with the Cox proportional hazard model. We did subgroup analyses with a model that included an interaction term corresponding to the test for heterogeneity in effects. Changes in lipid values were compared by repeated measures of ANOVA. Data were analysed with SAS statistical software (version 8.12).

### Role of the funding source

The sponsor had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The JELIS steering committee had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### Results

Patients were monitored for an average of 4.6 years (SD 1.1). Table 1 shows baseline characteristics of the treatment groups. The mean age of all patients was 61 years and 12 786 patients (69%) were women. Mean concentrations of total cholesterol and triglyceride were 7.1 mmol/L and 1.7 mmol/L; and mean LDL and HDL concentrations of total cholesterol and triglyceride were 4.7 mmol/L and 1.5 mmol/L, respectively. The webtable shows baseline characteristics for primary and secondary prevention subgroups. Of 3664 patients with documented coronary artery disease, 1050 had a history of myocardial infarction, 2903 of angina pectoris, and 895 angioplasty, stenting, or coronary artery bypass grafting.

Average doses were pravastatin 10.0 mg daily (SD 9.1) and simvastatin 5.6 mg daily (1.8). 16 449 (90%) patients took 10 mg pravastatin or 5 mg simvastatin. The 5-year follow-up rate was 16 971 (91%). Similar proportions of participants remained compliant in each treatment group. Study drug regimens were maintained until trial termination by 6151 (73%) of controls and in the treatment group. Study drug regimens were maintained until trial termination by 5883 (71%) of patients continued to take EPA and 6136 (74%) continued to take statin. 586 patients (262 assigned to EPA and 324 controls) reached the composite primary endpoint. Figure 2 shows Kaplan–Meier curves for the primary endpoint. The 5-year cumulative rate of major coronary events
was 2.8% in the EPA group and 3.5% in controls, resulting in a significant relative risk reduction of 19% in the EPA group (p=0.011). Figure 3 shows that EPA treatment was associated with a significant reduction of 24% in the frequency of unstable angina. The occurrence of coronary death or myocardial infarction was not significantly lower (22%) in the EPA group than in controls. The frequency of fatal or non-fatal myocardial infarction was not significantly reduced (23%) in the EPA group; however, that of non-fatal coronary events (including non-fatal myocardial infarction, unstable angina, and events of angioplasty, stenting, or coronary artery bypass grafting) was significantly lower (19%) in the EPA group than in controls.

Table 2 sets out major coronary events in the two treatment groups for comparison with specific background characteristics of all populations. For example, we grouped patients according to their LDL cholesterol at baseline. The relative reduction in major coronary events risk in the EPA group was of a similar magnitude in patients with different ranges of LDL cholesterol values, suggesting that LDL cholesterol is not an important factor in reduction of risk for major coronary events.

In the primary prevention subgroup, EPA treatment was associated with a non-significant 18% reduction in major coronary events. Figure 3 shows that EPA treatment was associated with a significant 19% reduction in major coronary events. EPA treatment was also associated with a significant 28% reduction in the incidence of unstable angina. This treatment also produced non-significant reductions of 25%, 25%, and 18% in coronary death or myocardial infarction, fatal or non-fatal myocardial infarction, and non-fatal coronary events, respectively.

In the other analyses, stroke occurred in 162 (1.7%) controls and 166 (1.8%) patients given EPA. Figure 3 shows that the frequency of ischaemic and haemorrhagic strokes did not differ between the two treatment groups, and neither did all-cause mortality.

Figure 4 summarises the change in lipid values after treatment. Total and LDL cholesterol at the last clinic visit decreased significantly by 19% and 25% from baseline in both groups, respectively. Triglyceride decreased significantly by 9% from baseline in the EPA group and by 4% in controls (p<0.0001 between groups). Both treatments produced only small changes in HDL cholesterol. The fatty acid concentrations at baseline were the average values for all patients who gave informed consent in the control group (n=8076) and the EPA group (n=8321). Plasma EPA at baseline was 2.9% of total molecules of fatty acids (mol %). To assess the effect of EPA treatment, plasma fatty acid values were compared for all patients who were still compliant after 5 years of observation (controls: n=4854, EPA group: n=4970). Plasma EPA concentration and the ratio of EPA to arachidonic acid at baseline were 93 mg/L and 0.60 in controls, and 97 mg/L and 0.63 in the EPA group, respectively. Plasma EPA concentration at year 5 was 169 mg/L in the EPA group, which was a 70% increase from baseline. The ratio of EPA to arachidonic acid increased two-fold from 0.63 to 1.23 in the EPA group. Similar results were reported previously.11,28

Table 3 shows that a quarter of patients in the EPA group had adverse experiences related to treatment, compared with about a fifth of controls. Rates of
discontinuation because of treatment-related adverse events were 1087 (11.7%) in the EPA group and 673 (7.2%) in the control group. Most adverse effects attributable to EPA allocation were regarded as mild. The following factors were more common in the EPA group than in controls: abnormal laboratory data; gastrointestinal disturbances such as nausea, diarrhoea, or epigastric discomfort; skin abnormalities such as eruption, itching, exanthema, or eczema; and haemorrhages such as cerebral and fundal bleedings, epistaxis, and subcutaneous bleeding. The frequency of new cancers did not differ.

Figure 3: Estimated hazard ratios of clinical endpoints stratified by prevention stratum
MI=myocardial infarction. CABG=coronary-artery bypass grafting. PTCA=percutaneous transluminal coronary angioplasty. CAD=coronary-artery disease.
Discussion

Our results show that EPA treatment reduced the frequency of major coronary events. The composite frequency of the primary endpoint in all patients for the EPA group was 19% lower than in controls. The risks of unstable angina and non-fatal coronary events were also substantially reduced, by 24% and 19%, respectively. The beneficial effects of EPA seemed much the same in both the secondary prevention and the primary prevention subgroups, although they were significant only in the EPA group because of greater numbers of events.

We showed that the reduced risk associated with EPA treatment was confined to non-fatal coronary events. However, the reduced risk did not apply to coronary death or sudden cardiac death in any of our study populations or secondary prevention subgroup studies. This finding differs from the results of previous interventional and observational studies. Most observational studies report that fish intake only once or twice a week or a small intake of fish about 30–60 g per day is associated with a 30–60% reduction in the risk of fatal coronary events or sudden cardiac deaths, but not of non-fatal coronary events. Secondary prevention trials for coronary heart disease report that a modest intake of fatty fish (200–400 g/week) or supplemental intake of EPA plus DHA (1 g/d) reduces coronary mortality by about 20–30% in patients who have already had a myocardial infarction. Experimental and epidemiological studies suggest that fish oil at low doses might prevent sudden cardiac death by an antiarrhythmic effect.

Our findings accord with a cohort study by the Japan Public Health Centre, which used a food-frequency questionnaire. Iso and co-workers reported that, compared with a small intake of fish (once a week or about 20 g per day), a high intake (eight times per week, or about 180 g per day) was associated with a substantially reduced risk of coronary heart disease, especially non-fatal cardiac events, in middle-aged Japanese men and women. This finding suggests that two protective mechanisms of EPA or n-3 polyunsaturated fatty acids affect the risk of coronary events: reduction of mortality from coronary artery disease and sudden cardiac death with a low intake of n-3 polyunsaturated fatty acid, and reduction of all coronary events with a high intake of n-3 polyunsaturated fatty acids. Our patients could possibly all have had intakes of fish that were above the threshold for prevention of fatal coronary events or sudden cardiac death. One potential explanation for the strong inverse association with non-fatal coronary events in our study population, but not in other study populations of non-Japanese patients, is that EPA might affect risk only at very high levels of fish intake, such as those common in Japan.

n-3 polyunsaturated fatty acids have antiarrhythmic effects and other beneficial effects, such as reduced n-3 polyunsaturated fatty acids have antiarrhythmic effects and other beneficial effects, such as reduced...
Table 3: Adverse experiences

<table>
<thead>
<tr>
<th>Condition</th>
<th>Control (n=9319)</th>
<th>EPA (n=9326)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newly diagnosed cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>2004 (21.7%)</td>
<td>2334 (25.3%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Stomach</td>
<td>37 (0.4%)</td>
<td>32 (0.3%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Lung</td>
<td>37 (0.4%)</td>
<td>32 (0.3%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Colorectal</td>
<td>29 (0.3%)</td>
<td>26 (0.3%)</td>
<td>0.68</td>
</tr>
<tr>
<td>Breast</td>
<td>21 (0.2%)</td>
<td>16 (0.2%)</td>
<td>0.41</td>
</tr>
<tr>
<td>Common adverse experiences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain (joint pain, lumbar pain, muscle pain)</td>
<td>180 (2.0%)</td>
<td>144 (1.6%)</td>
<td>0.04</td>
</tr>
<tr>
<td>Gastrointestinal disturbance (nausea, diarrhea, epigastric discomfort)</td>
<td>155 (1.7%)</td>
<td>357 (3.8%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Skin abnormality (eruption, itching, exanthema, eczema)</td>
<td>65 (0.7%)</td>
<td>160 (1.7%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Haemorrhage (cerebral, fundal, epistaxis, subcutaneous)</td>
<td>60 (0.6%)</td>
<td>105 (1.1%)</td>
<td>0.0006</td>
</tr>
<tr>
<td>Abnormal laboratory data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>322 (3.5%)</td>
<td>378 (4.1%)</td>
<td>0.03</td>
</tr>
<tr>
<td>CPK increased</td>
<td>116 (1.2%)</td>
<td>126 (1.4%)</td>
<td>0.52</td>
</tr>
<tr>
<td>GOT increased</td>
<td>38 (0.4%)</td>
<td>59 (0.6%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Sugar blood level increased</td>
<td>27 (0.3%)</td>
<td>38 (0.4%)</td>
<td>0.17</td>
</tr>
</tbody>
</table>

CPK=creatine phosphokinase. GOT=glutamic oxaloacetic transaminase.

platelet aggregation,41,42 vasodilation,43,44 antiproliferation,45 plaque-stabilisation,46 and a reduction in lipid action.46,47 One clinical study examined the morphology of endothelium in patients with fish oil supplementation and showed that fish-oil supplementation increased the stability of atherosclerotic plaque.33,34 Atherosclerotic plaque is vulnerable to rupture because it has a thin fibrous cap that covers a large lipid core, and an increased number of inflammatory cells such as macrophages. n-3 polyunsaturated fatty acids reduce the expression of adhesion molecules on endothelial cells35 and macrophages.36 Dietary fish oil reduces the production of chemoattractants, including leukotriene B4,37 platelet-derived growth factor,38 and monocyte chemoattractant protein-1.39 These mechanisms reduce the passage of monocytes and macrophages into the plaque. Thus, EPA and DHA reduce the numbers of macrophages in the atherosclerotic plaque. Thrombus formation in the ruptured plaque leads to acute cardiovascular events.

Our study has some specific characteristics. First, we used highly purified EPA rather than n-3 polyunsaturated fatty acids or fish oils. This trial is a pharmacological intervention rather than a food-based or nutrient trial. Nutritional data are difficult to extrapolate to pharmacological intervention because fish oil contains many fatty acids other than EPA and DHA. Although both EPA and DHA are biologically active, we do not know whether they have differential effects on cardiovascular protection. Second, our population was exclusively Japanese. In Japan, death from coronary artery disease is rare and the average dietary intake of fish is about five times higher than that in other countries.40 We did not use a food-frequency questionnaire to measure fish intake; instead, at baseline, we measured plasma fatty acid concentrations that indicate fish consumption and EPA intake. Plasma EPA was 2.9 mol% at baseline in our study population, which is similar to reports by Iso and co-workers40 that serum EPA composition was 4.1 mol% in rural Japanese and 2.4 mol% in urban Japanese; these values are much higher than those recorded in the USA, which are about 0.3 mol%.

Our trial has several limitations. First, we used an open interventional design, with blinded clinical endpoint assessment (PROBE design) to keep bias to a minimum.25 The PROBE design has the advantages of low costs and similarity to standard clinical practice, which should make the results easily applicable in routine medical care; however, we cannot exclude the possibility of bias in some of the physician-initiated endpoints, such as coronary revascularisation and hospital treatment for unstable angina.

Second, we prescribed either pravastatin or simvastatin for all participants as the first-line treatment, in part because these were the two statins available in the Japanese market at the start of this study. We used the low doses of statins that are recommended by Japan’s Ministry of Health, Labour, and Welfare. Such low doses have been reported to control serum lipid concentrations and major coronary events in Japanese patients.41,42 We did not use a true placebo group.

Third, this trial was substantially underpowered for analysis of subgroups. Death associated with coronary artery disease in the Japanese population is about 22–26 per 100 000 person-years, which is very low in comparison with that in the USA and northern Europe.28 This difference is thought to be partly due to differences in dietary habits, including fish consumption. About two-thirds of patients in our study were women, who have an incidence of coronary events that is 2–3 times lower than that for men.43 This low ratio of men to women and the Japanese study population could have contributed to the overall low rate of coronary events, including coronary death, which failed to detect a significant effect on primary prevention outcomes.

Studies show that use of high-dose statin treatment can produce an extra reduction in cardiac events, by achievement of the maximum lowering of LDL cholesterol.44 Similar benefits could arguably be obtained if the dose of statin was increased without the addition of EPA; however, we noted that EPA did not affect LDL cholesterol concentrations and that this 19% reduction in major coronary events in the EPA group was not related to serum LDL cholesterol. This finding suggests that EPA exerts its effects via mechanisms that are independent of a reduction in LDL cholesterol.
We adopted the most widely used therapeutic dose of EPA (1800 mg per day), which is approved by Japan’s Ministry of Health, Labour, and Welfare. We noted no significant difference in all-cause mortality between the treatment and control groups. There was no difference in the rate of cancer and stroke, including cerebral bleeding, subarachnoidal bleeding, or both. We do not know whether lower or higher doses of EPA would produce different effects from those noted at the dose used in our study.

The beneficial effects of EPA could have stemmed from many biological effects that lead to the attenuation of thrombosis, inflammation, and arrhythmia in addition to a reduction of triglycerides. Overall, this study shows that EPA, at a dose of 1800 mg per day, is a very promising regimen for prevention of major coronary events, especially since EPA seems to act through several biological mechanisms. Because our population was exclusively Japanese, we cannot generalise our results to other populations. We need to investigate whether EPA is effective for prevention of major coronary events in hypercholesterolaemic patients without or with coronary artery disease in other countries.

Contributors
Investigators on the steering committee of the study designed, conducted, analysed, and interpreted the present study. A statistical coordination centre collected, managed, and analysed the data. All authors have participated in the data analysis and reporting stage of this manuscript. The principal investigator prepared the first draft, and all members of the JELIS Steering Committee contributed to writing, and have seen and approved the final version.

Conflict of interest statement
The committee members and investigators received no remuneration for conducting this study. M Yokoyama received travel costs from Mochida Pharmaceutical Co Ltd, Tokyo, Japan, to participate in the scientific meeting. Other authors have no conflicts of interest.

Acknowledgments
This study was supported by grants from Mochida Pharmaceutical Co Ltd, Tokyo, Japan. The results were presented in part at the late-breaking clinical trials of the American Heart Association Annual Meeting, Dallas, TX, USA, Nov, 13–16, 2005. We thank all trial participants and the large numbers of doctors, nurses, and hospital staff who made long-term commitments to the study.

References
15 Kawano H, Yano T, Mizuguchi K, Mochizuki H, Saito Y. Changes in aspects such as the collagenous fiber density and cell foam size of atherosclerotic lesions composed of foam cells, smooth muscle cells and fibrous components in rabbits caused by all-cis-5, 8, 11, 14, 17-eicosapentaenoic acid. J Atheroscler Thromb 2002; 9: 170–77.
26 Hansson L, Hedner T, Dahlöf B. Prospective randomized open
blinded end-point (PROBE) study. A novel design for intervention
trials. Prospective Randomized Open Blinded Endo-Point.

27 Yokoyama M, Origasa H; JELIS Investigators. Effects of
eicosapentaenoic acid on cardiovascular events in Japanese patients
with hypercholesterolemia: rationale, design, and baseline
characteristics of the Japan EPA Lipid Intervention Study (JELIS).

28 Nakamura T, Azuma A, Kuribayashi T, Sugihara H, Okuda S,
Nakagawa M. Serum fatty acid levels, dietary style and coronary
heart disease in three neighbouring areas in Japan: the Kumihama

29 He K, Song Y, Daviglus ML, Liu K, et al. Accumulated evidence on
fish consumption and coronary heart disease mortality: a meta-

30 Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by

31 Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n3 fatty
acids and risk of coronary heart disease among Japanese: the Japan
Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006;

32 Harris WS, Park Y, Isley WL. Cardiovascular disease and long-chain

33 Din N, Newby DE, Flapan AD. Omega 3 fatty acids and
328: 30–35.

34 Thies F, Garry JM, Yaqoob P, et al. Association of n-3
polyunsaturated fatty acids with stability of atherosclerotic plaques:

35 Chen H, Li D, Chen J, Robert GJ, Saldeen T, Mehta JL. EPA and
DHA attenuate ox-LDL-induced expression of adhesion molecules
in human coronary artery endothelial cells via protein kinase B

36 Miles EA, Wallace FA, Calder PC. Dietary fish oil reduces
intercellular adhesion molecule 1 and scavenger receptor expression

37 Terano T, Salminen JA, Moncada S. Effect of orally administered
eicosapentaenoic acid (EPA) on the formation of leukotriene B4 and
leukotriene B5 by rat leukocytes. Biochem Pharmacol 1984; 33:
3071–76.

38 Wallace JM, Turley E, Gilmore WS, Strain J. Dietary fish oil
supplementation alters leukocyte function and cytokine production

39 Baumann KH, Hessell F, Laras I, et al. Dietary omega-3, omega-6,
and omega-9 unsaturated fatty acids and growth factor and cytokine
gene expression in unstimulated and stimulated monocytes. A
randomized volunteer study. Arterioscler Thromb Vasc Biol 1999; 19:
59–66.

40 Iso H, Sato S, Folsom AR, et al. Serum fatty acids and fish intake in
rural Japanese, urban Japanese, Japanese American and Caucasian

41 Matsuzaki M, Kita T, Mabuchi H, et al. Large scale cohort study of
the relationship between serum cholesterol concentration and
coronary events with low-dose simvastatin therapy in Japanese
patients with hypercholesterolemia: primary prevention cohort
study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002;
66: 1087–95.

42 Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of
cardiovascular disease with pravastatin in Japan (MEGA study): a

43 LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering
with atorvastatin in patients with stable coronary disease.